A nutritional biomarker score of the Mediterranean diet and incident type 2 diabetes: Integrated analysis of data from the MedLey randomised controlled trial and the EPIC-InterAct case-cohort study

Author:

Sobiecki Jakub G.ORCID,Imamura FumiakiORCID,Davis Courtney R.ORCID,Sharp Stephen J.ORCID,Koulman AlbertORCID,Hodgson Jonathan M.ORCID,Guevara MarcelaORCID,Schulze Matthias B.ORCID,Zheng Ju-ShengORCID,Agnoli ClaudiaORCID,Bonet Catalina,Colorado-Yohar Sandra M.ORCID,Fagherazzi GuyORCID,Franks Paul W.ORCID,Gundersen Thomas E.,Jannasch FranziskaORCID,Kaaks Rudolf,Katzke VerenaORCID,Molina-Montes EstherORCID,Nilsson Peter M.ORCID,Palli Domenico,Panico Salvatore,Papier KerenORCID,Rolandsson Olov,Sacerdote CarlottaORCID,Tjønneland AnneORCID,Tong Tammy Y. N.ORCID,van der Schouw Yvonne T.ORCID,Danesh John,Butterworth Adam S.ORCID,Riboli ElioORCID,Murphy Karen J.,Wareham Nicholas J.ORCID,Forouhi Nita G.ORCID

Abstract

Background Self-reported adherence to the Mediterranean diet has been modestly inversely associated with incidence of type 2 diabetes (T2D) in cohort studies. There is uncertainty about the validity and magnitude of this association due to subjective reporting of diet. The association has not been evaluated using an objectively measured biomarker of the Mediterranean diet. Methods and findings We derived a biomarker score based on 5 circulating carotenoids and 24 fatty acids that discriminated between the Mediterranean or habitual diet arms of a parallel design, 6-month partial-feeding randomised controlled trial (RCT) conducted between 2013 and 2014, the MedLey trial (128 participants out of 166 randomised). We applied this biomarker score in an observational study, the European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct case-cohort study, to assess the association of the score with T2D incidence over an average of 9.7 years of follow-up since the baseline (1991 to 1998). We included 22,202 participants, of whom 9,453 were T2D cases, with relevant biomarkers from an original case-cohort of 27,779 participants sampled from a cohort of 340,234 people. As a secondary measure of the Mediterranean diet, we used a score estimated from dietary-self report. Within the trial, the biomarker score discriminated well between the 2 arms; the cross-validated C-statistic was 0.88 (95% confidence interval (CI) 0.82 to 0.94). The score was inversely associated with incident T2D in EPIC-InterAct: the hazard ratio (HR) per standard deviation of the score was 0.71 (95% CI: 0.65 to 0.77) following adjustment for sociodemographic, lifestyle and medical factors, and adiposity. In comparison, the HR per standard deviation of the self-reported Mediterranean diet was 0.90 (95% CI: 0.86 to 0.95). Assuming the score was causally associated with T2D, higher adherence to the Mediterranean diet in Western European adults by 10 percentiles of the score was estimated to reduce the incidence of T2D by 11% (95% CI: 7% to 14%). The study limitations included potential measurement error in nutritional biomarkers, unclear specificity of the biomarker score to the Mediterranean diet, and possible residual confounding. Conclusions These findings suggest that objectively assessed adherence to the Mediterranean diet is associated with lower risk of T2D and that even modestly higher adherence may have the potential to reduce the population burden of T2D meaningfully. Trial registration Australian New Zealand Clinical Trials Registry (ANZCTR) ACTRN12613000602729 https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=363860.

Funder

National Health and Medical Research Council

Sixth Framework Programme

MRC Cambridge Initiative

Medical Research Council

British Heart Foundation

Seventh Framework Programme

European Research Council

NIHR Cambridge Biomedical Research Centre

Health Data Research UK

Centre International de Recherche sur le Cancer

School of Public Health, Imperial College London

NIHR Imperial Biomedical Research Centre

Danish Cancer Society

Ligue Contre le Cancer

Institut Gustave-Roussy

Mutuelle Générale de l’Education Nationale

Institut National de la Santé et de la Recherche Médicale

German Cancer Aid

German Cancer Research Center

German Institute of Human Nutrition Potsdam-Rehbruecke

Bundesministerium für Bildung und Forschung

Associazione Iblea per la Ricerca Epidemiologica

Associazione Italiana per la Ricerca sul Cancro

Compagnia di San Paolo

National Research Council and Sicilian Regional Government

Ministerie van Volksgezondheid, Welzijn en Sport

Netherlands Cancer Registry

LK Research Funds

Dutch Prevention Funds

Zorg Onderzoek Nederland

Wereld Kanker Onderzoek Fonds

Statistics Netherlands

Instituto de Salud Carlos III

Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra

Catalan Institute of Oncology

Swedish Cancer Society

Swedish Research Council

Councils of Skåne and Västerbotten

Cancer Research UK

Federal Ministry of Education and Research and the State of Brandenburg

Westlake University

H2020 Marie Skłodowska-Curie Actions

Novo Nordisk

Swedish Diabetes Association

Swedish Heart-Lung Foundation

Imperial College Biomedical Research Centre

Publisher

Public Library of Science (PLoS)

Subject

General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3